Health and Healthcare

What This FDA Approval Means for STAAR Surgical

courtesy of the U.S. Food and Drug Administration

STAAR Surgical Co. (NASDAQ: STAA) shares made a handy gain on Friday after the firm announced a key approval by the U.S. Food and Drug Administration (FDA).

The FDA granted the approval of the PMA Supplement for the Visian Toric Implantable Collamer Lens (ICL) for the correction of myopia with astigmatism.

Overall, this approval represents a meaningful expansion of the ICL product line for the correction of refractive error in patients with both myopia and astigmatism, which are common conditions in the United States. Astigmatism affects roughly 30% of the population.

Patients have described ICL surgery as “life-changing” or wished they had opted for the surgery sooner. The ICL in both spherical and toric designs has been associated with significant improvements in quality of life. The approval of the Visian Toric ICL is also an important step toward the future availability of advanced ICL models in the United States, such as the EVO/EVO+ Toric ICL.

Caren Mason, president and CEO, commented:

FDA’s approval of STAAR’s Visian Toric ICL in the U.S. provides an exciting treatment option for myopic patients with astigmatism in search of visual freedom. We are thrilled to be able to offer this lens in the United States and look forward to officially making the Visian Toric ICL available to U.S. surgeons for their patients on November 1st, 2018.

Shares of STAAR were last seen up about 3% at $52.15, with a consensus analyst price target of $49.00 and a 52-week range of $10.75 to $51.40.

Take Charge of Your Retirement In Just A Few Minutes (Sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.

Here’s how it works:

  1. Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
  2. Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
  3. Choose Your  Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.

Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!

 

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.